Completed PHASE2 NCT00101608

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium

Sponsor: Bristol-Myers Squibb

Conditions Bladder Cancer Bladder Neoplasms Kidney Neoplasms Neoplasm, Bladder Transitional Cell Carcinoma Ureter Neoplasms

Interventions vinflunine

Updated 8 times since 2017 Last updated: Feb 27, 2010 Started: Jan 31, 2005 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

A PHASE2 clinical study on Bladder Cancer and Bladder Neoplasms, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 8 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Pierre Fabre Medicament

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Adelaide, Australia , Ann Arbor, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Bangkok, Thailand , Beverly Hills, United States , Buffalo, United States , Burlington, United States and 65 more locations